BSE filing, NSE: CSURGSU. Summary written from the filing by ALFA Finder's alert engine.
Centenial Surgical Suture Ltd: key numbers
- Share price
- ₹71.96
- Market cap
- ₹26.25 Cr
- Revenue (annual)
- ₹53.84 Cr
- Net profit (annual)
- ₹-2.20 Cr
- P/E (TTM)
- -18.2×Sector 54.5×
- Promoter holding
- 46.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Centenial Surgical Suture Ltd
All →Centenial Surgical Suture Other Announcement
Centenial Surgical Suture Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Centenial Surgical Suture Price Movement Clarification
Centenial Surgical Sute reports abnormal share-price movement unsupported by any corporate news and requests BSE/SEBI investigation into suspected manipulative trades. The company states no material announcement explains the unusual price action.
Centenial Surgical Suture Management Change
Anuradha Kashikar has resigned from her position as Executive Director and Key Managerial Personnel (KMP) of Centenial Surgical Suture Ltd, effective October 5, 2026.
Centenial Surgical Suture Annual General Meeting
Centenial Surgical Suture Ltd announced results for its Annual General Meeting held on September 28, 2026. All three resolutions were passed with the requisite majority.
Centenial Surgical Suture Management Change
Centenial Surgical Suture Ltd has appointed Ms. Sapna Mhatre as Chief Financial Officer, succeeding Ms. Anuradha Kashikar, who resigned from the position effective August 14, 2026.
Centenial Surgical Suture Annual Report
Centenial Surgical Suture Ltd has filed its 31st Annual Report for the financial year 2025-2026 as per SEBI (LODR) Regulations.
Other debt & borrowing announcements
All →Brigade Enterprises Debt & Borrowing
Brigade Enterprises' subsidiary Venusta Ventures will issue rated NCDs to IFC under an investment framework agreement. No amount is disclosed in the filing.
Max Estates Debt & Borrowing: ₹350 Cr
Max Estates' board approved a ₹350 crore corporate guarantee for a wholly-owned subsidiary's term loan. Monitoring agency reports on its QIP and warrant proceeds were also filed.
- Value
- ₹350.0 Cr
Credent Connect N Care Debt & Borrowing: ₹4.5 Cr
Credent Connect N Care's board approved an unsecured inter-corporate loan of Rs 4.50 Crore to Kartavya Healtheon Private Limited. The loan carries 12% compounded interest after 25 November 2026 and gives the lender a right to up to 26% equity.
- Value
- ₹4.50 Cr
Amines & Plasticizers Debt & Borrowing
Amines & Plasticizers invited members to place unsecured deposits under Form DPT-1. Only resident members may subscribe, and the scheme is on the company website.
HEG Advanced Materials Debt & Borrowing: ₹50 Cr
HEG granted subsidiary Replus Engitech an unsecured revolving loan of Rs.50 Crore. It is repayable on demand at 9% interest, at arm's length.
- Value
- ₹50.00 Cr
- Execution
- Repayable on demand
Purple Finance Debt & Borrowing: ₹25 Cr
Purple Finance's finance committee approved issuing up to 25,000 senior secured NCDs aggregating ₹25 Crore on a private placement basis. The debentures carry an 11.50% coupon and a 30-month tenure.
- Value
- ₹25.00 Cr
- Execution
- 30 months from deemed date of allotment